Patients with sleep-disordered breathing who used CPAP after a stroke or transient ischemic attack had lower odds of another cerebrovascular event in a new evidence review, though the result remains sensitive to treatment adherence and differences among studies.
The systematic review and meta-analysis published in European Neurology by Jeppe Suusgaard and colleagues brought together 30 studies involving 3,381 adults, including 19 randomized trials and 11 observational studies. Its primary questions were recurrent stroke or TIA and all-cause mortality—not whether CPAP can reverse neurological injury.
Across seven randomized trials that reported recurrent events, CPAP was associated with about half the odds of another stroke or TIA compared with sham treatment, usual care or nonadherence. The pooled odds ratio was 0.49, with a 95 percent confidence interval of 0.25 to 0.95. Because the upper bound sits close to no difference, the result is encouraging rather than definitive.
Sleep-disordered breathing—particularly obstructive sleep apnea—is common after stroke. Repeated airway obstruction can fragment sleep, lower oxygen intermittently and trigger sympathetic and blood-pressure surges. Those effects provide a plausible reason to identify and treat apnea during recovery, when attention, energy and cardiovascular stability can all matter.
Using CPAP after a stroke is not always straightforward. Weakness, cognitive changes, facial asymmetry and dependence on caregivers can complicate mask fitting and nightly use. Trials also began treatment at different points, measured outcomes differently and achieved varying adherence. A device cannot provide therapeutic exposure while it remains off, but patients able to use it consistently may also differ from those who cannot.
That self-selection issue is especially important in observational evidence. The review found no change in short-term mortality in randomized trials. Lower long-term mortality appeared in unadjusted observational data, which cannot establish that CPAP caused the difference. Signals of improved function, cognition and sleepiness were inconsistent and generally stronger among people with high adherence.
Earlier research points in the same direction without closing the question. A 2023 meta-analysis of randomized trials reported fewer recurrent vascular events and possible improvements in several recovery measures, but also substantial heterogeneity. The American Academy of Sleep Medicine’s positive-airway-pressure guideline emphasizes objective diagnosis, follow-up and troubleshooting rather than treating a machine prescription as the end of care.
The new review makes screening after stroke more consequential, but it does not turn CPAP into a neurological repair therapy. The next generation of trials must pair clinical outcomes with realistic
adherence support and ask whether benefits extend to mobility, cognition and independence. The promise of post-stroke CPAP will depend not only on whether it works while worn, but on whether recovering patients can use it night after night.
